However, different randomized trials have reported conflicting results about the therapeutic benefit [46, 47, 48 and the development of targeted therapies and discovery of new immunomodulating drugs have largely replaced adjuvant therapy in melanoma patients with IFN‐alpha [49]. The gene discussed is IFNA1; the disease is melanoma.